Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial

PURPOSE: To investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. METHODS: Patients in group A (aged < 65 years with homologous recombination deficiency, HRD, score ≥ 42, or those at any age with germline BRCA mutation, gBRCAm...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Bando, Hiroko, Yamanaka, Takashi, Kadoya, Takayuki, Takahashi, Masato, Nagai, Shigenori E., Ohtani, Shoichiro, Aruga, Tomoyuki, Suzuki, Eiji, Kikawa, Yuichiro, Yasojima, Hiroyuki, Kasai, Hiroi, Ishiguro, Hiroshi, Kawabata, Hidetaka, Morita, Satoshi, Haga, Hironori, Kataoka, Tatsuki R., Uozumi, Ryuji, Ohno, Shinji, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233289/
https://www.ncbi.nlm.nih.gov/pubmed/33763789
http://dx.doi.org/10.1007/s10549-021-06184-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233289/
https://www.ncbi.nlm.nih.gov/pubmed/33763789
http://dx.doi.org/10.1007/s10549-021-06184-w

Ejemplares similares